Refinement in radiotherapy treatment for locally advanced cervical cancer: a historic perspective

Locally advanced cervical cancer remains a major global health challenge, with outcomes and access disparities greatest in low-middle income countries. Since the 1999 National Cancer Institute clinical alert endorsing concurrent chemoradiation as standard of care, advances in external beam radiotherapy and brachytherapy have improved disease control and toxicity profiles. Whether these advances constitute true treatment de-escalation remains uncertain. This narrative review synthesizes historical milestones and contemporary evidence in definitive radiotherapy for locally advanced cervical cancer, focusing on strategies that may enable de-escalation: refined external beam radiation therapy techniques and volumes, optimized treatment time, systemic therapy, and modernization of brachytherapy. Landmark trials eliminated routine surgery after radiation therapy and established concurrent chemoradiation as the backbone of care. Technologic evolution from 2- to 3-dimensional conformal radiotherapy to intensity-modulated radiotherapy/volumetric arc therapy and image-guided adaptive brachytherapy has reduced toxicity while maintaining and even improving control. EMBRACE I/II benchmarked magnetic resonance imaging-guided adaptive brachytherapy and modern external beam radiotherapy, demonstrating high local control with lower severe morbidity and wider adoption of combined intracavitary/interstitial techniques. De-escalation by precision includes selective use of extended-field radiation, abandonment of pelvic sidewall boosts, and simultaneous integrated boost to nodal disease to avoid prolonging overall treatment time. True dose, volume, and time-reducing strategies remain investigational. Current progress reflects optimization and refinement rather than definitive de-escalation of locally advanced cervical cancer radiotherapy. Realizing de-escalation will require improving universal access to state-of-the-art external beam radiation and brachytherapy, rigorously designed trials, and in the future, biologically guided patient selection to deliver less intensive, yet equally curative treatment.